AR071541A1 - Inhibidores de la polimerasa virica - Google Patents

Inhibidores de la polimerasa virica

Info

Publication number
AR071541A1
AR071541A1 ARP080103381A ARP080103381A AR071541A1 AR 071541 A1 AR071541 A1 AR 071541A1 AR P080103381 A ARP080103381 A AR P080103381A AR P080103381 A ARP080103381 A AR P080103381A AR 071541 A1 AR071541 A1 AR 071541A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
independently selected
het
optionally substituted
Prior art date
Application number
ARP080103381A
Other languages
English (en)
Inventor
Timothy A Stammers
Pierre L Beaulieu
Martin Poirier
Jean Rancourt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR071541A1 publication Critical patent/AR071541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Son utiles como inhibidores de la polimerasa NS5B del virus de la hepatitis C. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1): en donde: X se selecciona de O y S; R2 es Het o arilo, opcionalmente sustituido con 1 a 5 sustituyentes R20, en donde R20, en cada caso, se selecciona independientemente de: a) halogeno, ciano o nitro; b) R7, -C(=O)-R7, -C(=O)-O-R7, -O-R7, -S-R7, -SO-R7, -SO2-R7, -alquilen C1-6-R7, -alquilen C1-6-C(=O)-R7, -alquilen C1-6-C(=O)-O-R7, -alquilen C1-6-O-R7, alquilen C1-6-S-R7, alquilen C1-6-SO-R7 o alquilen C1-6-SO2-R7; en donde R7 en cada caso se selecciona independientemente de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogenoalquilo C1-6, cicloalquilo C3-7, arilo y Het; en donde el alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, y alquileno C1-6 están opcionalmente sustituidos con 1 o 2 sustituyentes, cada uno independientemente seleccionado de -OH, -alquilo C1-6, halogeno, -halogenoalquilo C1-6, cicloalquilo C3-7, -O-alquilo C1-6, ciano, COOH, -NH2, -NH-alquilo C1-4, -Nhcicloalquilo C3-7, -N(alquil C1-4)cicIoalquilo 3-7 y -N(alquilo C1-4)2; y en donde cada uno del arilo y Het está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado de i) halogeno, ciano, oxo, tioxo, imino, -OH, -O-alquilo C1-6, -O-halogenoalquilo C1-6, cicloalquilo C3-7, halogenoalquilo C1-6, -C(=O)-alquilo C1-6, -SO2-alquilo C1-6, -C(=O)-NH2, -C(=O)-NH-alquilo C1-4, -C(=O)-N(alquilo C1-4)2, -C(=O)-NH-cicloalquilo C3-7, -C(=O)-N(alquil C1-4)-cicloalquilo C3-7, -NH2, -Nhalquilo C1-4, -N(alquilo C1-4)2, -NH-cicloalquilo C3-7, -N(alquil C1-4)-cicloalquilo C3-7 o -NH-C(=O)-alquilo C1-4; ii) alquilo C1-6 opcionalmente sustituido con -OH, -O-halogenoalquilo C1-6 o -O-alquilo C1-6; y iii) arilo o Het, en donde cada uno del arilo y Het está opcionalmente sustituido con halo o alquilo C1-6; y c) -N(R8)R9, -C(=O)-N(R8)R9, -O-C(=O)-N(R8)R9, -SO2-N(R8)R9, -alquilen C1-6-N(R8)R9, -alquilen C1-6-C(=O)-N(R8)R9, -alquilen C1-6-O-C(=O)-N(R8)R9 o -alquilen C1-6-SO2-N(R8)R9; en donde el alquileno C1-6 está opcionalmente sustituido con 1 o 2 sustituyentes, cada uno independientemente seleccionado de -OH, -alquilo C1-6, halogeno, -halogenoalquilo C1-6, cicloalquilo C3-7, -O-alquilo C1-6, ciano, COOH, -NH2, -NH-alquilo C1-4, -NH-cicloaIquilo C3-7, -N(alquil C1-4)cicloalquiIo C3-7 y -N(alquilo C1-4)2; R8 en cada caso se selecciona independientemente de H, alquilo C1-6 y cicloalquilo C3-7; y R9 en cada caso se selecciona independientemente de R7, -O-alquilo C1-6, -alquilen C1-6-R7, -SO2-R7, -C(=O)-R7, -C(=O)OR7 y -C(=O)N(R8)R7; en donde R7 y R8 son como se han definido antes; o R8 y R9, junto con el N al que están unidos, están unidos para formar un heterociclo de 4 a 7 miembros que además opcionalmente contiene 1 a 3 heteroátomos, cada uno independientemente seleccionado de N, O y S, en donde cada heteroátomo de S, independientemente y cuando sea posible, puede existir en un estado oxidado de modo que está además unido a uno o dos átomos de oxígeno para formar los grupos SO o SO2, en donde el heterociclo está opcionalmente sustituido con 1 a 3 sustituyentes cada uno independientemente seleccionado de alquilo C1-6, halogenoalquilo C1-6, halogeno, oxo, -OH, SH, -O-alquilo C1-6, S-alquilo C1-6, cicloalquilo C3-7, -NH2, -NH-alquilo C1-6, -N(alquilo C1-6)2, -NH-cicloalquilo C3-7, -N(alquil C1-4)cicloalquilo C3-7, -C(=O)-alquilo C1-6 y -NHC(=O)-alquilo C1-6; R3 se selecciona de H, halogeno, CN, alquilo C1-4, -OH, -O-alquilo C1-4, -S-alquilo C1-4, -NH, -NH-alquilo C1-4, -NH-cicloalquilo C3-7, -N(alquil C1-4)cicloalquilo C3-7 y N(alquilo C1-4)2; R5 es H, alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6- o Het; el alquilo C1-6 y el Het están cada uno opcionalmente sustituido con 1 a 4 sustituyentes, cada uno independientemente seleccionado de alquilo C1-6, halogenoalquilo C1-6, cicloalquilo C3-7, Het, -OH, -COOH, -C(=O)-alquilo C1-6, -C(=O)-O-alquilo C1-6, -SO2-alquilo C1-6) y -C(=O)-N(R51)R52; en donde R51 es H, alquilo C1-6 o cicloalquilo C3-7; y R52 es H, alquilo C1-6, cicloalquilo C3-7, arilo, Het, aril-alquilo C1-3- o Het-alquilo C1-3-; en donde cada uno de los alquilo C1-6, cicloalquilo C3-7, arilo, Het, aril-alquilo C1-3- y Het-alquilo C1-3- está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado de alquilo C1-6, halogenoalquilo C1-6, halogeno, oxo, -OH, -O-aIquiIo C1-6, -NH2, -NH-alquilo C1-6), -N(alquilo C1-6)2, -NH-cicloalquilo C3-7, -N(alquil C1-4)cicloalquilo C3-7, -C(=O)alquilo C1-6 y -NHC(=O)-alquilo C1-6; en donde el alquilo C1-6 está opcionalmente sustituido con OH; o R51 y R52, junto con el N al que están unidos, están unidos para formar un heterociclo de 4 a 7 miembros que además opcionalmente contiene 1 a 3 heteroátomos, cada uno independientemente seleccionado de N, O y S, en donde cada heteroátomo de S, independientemente y cuando sea posible, puede existir en un estado oxidado de modo que está además unido a uno o dos átomos de oxígeno para formar los grupos SO o SO2; en donde el heterociclo está opcionalmente sustituido con 1 a 3 sustituyentes cada uno independientemente seleccionado de alquilo C1-6, halogenoalquilo C1-6, halogeno, oxo, -OH, -O-alquilo C1-6, -NH2, -NH-alquilo C1-6, -N(alquilo C1-6)2, -Nhcicloalquilo C3-7), -N(alquil C1-4)cicloalquilo C3-7, -C(=O)-alquilo C1-6 y -NHC(=O)-alquilo C1-6; en donde el alquilo C1-6 está opcionalmente sustituido con OH; R6 es Het; que está opcionalmente sustituido con 1 a 5 sustituyentes, cada uno independientemente seleccionado de halogeno, alquilo C1-6, halogenoalquilo C1-6, cicloalquilo C3-7, -OH, -SH, -O-alquilo C1-4, -S-alquilo C1-4 y -N(R8)R9; en donde R8 y R9 son como se ha definido antes; y Het es un heterociclo de 4 a 7 miembros saturado, insaturado o aromático que tiene 1 a 4 heteroátomos, cada uno independientemente seleccionado de O, N y S, o un heteropoliciclo de 7 a 14 miembros saturado, insaturado o aromático que tiene, donde sea posible, 1 a 5 heteroátomos, cada uno independientemente seleccionado de O, N y S; en donde cada heteroátomo de N, independientemente y cuando sea posible, puede existir en un estado oxidado de modo que además está unido a un átomo de oxígeno para formar un grupo N-oxido y en donde cada heteroátomo de S, independientemente y cuando sea posible, existe en un estado oxidado de modo que está además unido a uno o dos átomos de oxigeno para formar los grupos SO o SO2 o una de sus sales o ésteres; con la salvedad que cuando X es O, R2 es fenilo, R3 es H y R5 es H, entonces R6 no es como en formula 2.
ARP080103381A 2007-08-03 2008-08-01 Inhibidores de la polimerasa virica AR071541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95370107P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
AR071541A1 true AR071541A1 (es) 2010-06-30

Family

ID=40340909

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103381A AR071541A1 (es) 2007-08-03 2008-08-01 Inhibidores de la polimerasa virica

Country Status (7)

Country Link
US (1) US8242140B2 (es)
EP (1) EP2188274A4 (es)
JP (1) JP2010535156A (es)
AR (1) AR071541A1 (es)
CA (1) CA2693997C (es)
TW (1) TW200916102A (es)
WO (1) WO2009018657A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
CA2693495A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EA201000948A1 (ru) * 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
US8410091B1 (en) 2009-09-11 2013-04-02 Boehringer Ingelheim International Gmbh Process for preparation of substituted 2-amino-5-(5-(heterocyclemethyl)pyridin-2-yloxy)benzoic acid
US8519176B1 (en) * 2009-10-05 2013-08-27 Boehringer Ingelheim International Gmbh Process for preparation of substituted P-aminophenol
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN103601671B (zh) * 2013-10-22 2016-08-17 上海泰坦科技股份有限公司 碘代三氟甲基吡啶的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507457A (en) 1974-11-12 1978-04-12 Agfa Gevaert Fixer compositions used in planographic printing
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU780698B2 (en) * 1999-07-20 2005-04-14 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
HUP0202263A3 (en) 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
US6434489B1 (en) 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
RU2002129564A (ru) 2000-04-05 2004-05-10 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с
IL151935A0 (en) 2000-04-19 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2410682A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR100939155B1 (ko) 2000-07-21 2010-01-28 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
DE60138567D1 (de) 2000-12-12 2009-06-10 Schering Corp Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
WO2002070739A2 (en) 2001-03-08 2002-09-12 Boehringer Ingelheim (Canada) Ltd Assay for identifying inhibitors of the rna dependent rna polymerase (ns5b) of hcv
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
GB0201179D0 (en) * 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CN100352819C (zh) 2002-01-23 2007-12-05 先灵公司 作为ns3－丝氨酸蛋白酶抑制剂的脯氨酸化合物用于制备治疗丙型肝炎病毒感染的药物
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2480583C (en) 2002-04-01 2008-07-15 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
JP4602076B2 (ja) * 2002-06-04 2010-12-22 ネオジェネシス ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
BR0314721A (pt) 2002-10-23 2005-08-02 Glenmark Pharmaceuticals Ltd Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
JP2004168707A (ja) * 2002-11-20 2004-06-17 Bayer Cropscience Ag イソチアゾリルベンゾオキサジン誘導体および病害防除剤
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CA2522561C (en) 2003-04-18 2012-07-17 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
ES2456702T3 (es) 2003-05-09 2014-04-23 Boehringer Ingelheim International Gmbh Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C
BRPI0410456B8 (pt) 2003-05-21 2021-05-25 Boehringer Ingelheim Int compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
ATE500264T1 (de) 2003-09-22 2011-03-15 Boehringer Ingelheim Int Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
US7592419B2 (en) 2003-09-26 2009-09-22 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005049622A1 (ja) 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005051980A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2005058821A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
EA013207B1 (ru) 2004-02-20 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
WO2005087730A1 (en) 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20070026394A (ko) 2004-02-27 2007-03-08 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3 세린 프로테아제 억제제로서사이클릭 ｐ4'ｓ를 지닌 신규한 케토아미드
CA2557322A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
TW200602037A (en) 2004-02-27 2006-01-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005085197A1 (en) 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
AU2005222060A1 (en) 2004-02-27 2005-09-22 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
EP1763531A4 (en) 2004-06-28 2009-07-01 Boehringer Ingelheim Int ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
PE20060569A1 (es) 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ES2366478T3 (es) 2004-07-20 2011-10-20 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
US20060025480A1 (en) 2004-08-02 2006-02-02 Boehringer Ingelheim International Gmbh Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors
KR20070083939A (ko) * 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
SI1919898T1 (sl) * 2005-07-29 2011-05-31 Tibotec Pharm Ltd Makrociklični inhibitorji virusa hepatitisa C
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
CN101754970B (zh) 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
CA2693495A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2009077497A2 (de) 2007-12-19 2009-06-25 Basf Se Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
WO2009077608A1 (en) 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
TWI432421B (zh) 2007-12-19 2014-04-01 Du Pont 製備２－胺基－５－氰基苯甲酸衍生物之方法
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
EP2222632A1 (en) 2007-12-19 2010-09-01 Glaxo Group Limited Compounds which potentiate the ampa receptor and uses thereof in medicine
CN101945580A (zh) 2007-12-19 2011-01-12 巴斯夫欧洲公司 唑基甲基环氧乙烷、其应用和包含它们的组合物
WO2009077500A2 (de) 2007-12-19 2009-06-25 Basf Se Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
EP2224812A2 (de) 2007-12-19 2010-09-08 Basf Se Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
SI2222675T1 (sl) 2007-12-19 2013-12-31 Genentech, Inc. 5-anilinoimidazopiridini in postopki za uporabo
JP2012504556A (ja) 2008-10-03 2012-02-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤

Also Published As

Publication number Publication date
JP2010535156A (ja) 2010-11-18
TW200916102A (en) 2009-04-16
WO2009018657A1 (en) 2009-02-12
US8242140B2 (en) 2012-08-14
EP2188274A4 (en) 2011-05-25
CA2693997C (en) 2013-01-15
CA2693997A1 (en) 2009-02-12
EP2188274A1 (en) 2010-05-26
US20100190779A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
AR069832A1 (es) Inhibidores de la polimerasa virica
AR071541A1 (es) Inhibidores de la polimerasa virica
AR069544A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana y composiciones farmaceuticas que los contienen
AR069334A1 (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana
AR078396A1 (es) Inhibidores de la polimerasa virica y composiciones farmaceuticas que los contienen
AR062423A1 (es) Inhibidores de la polimerasa virica
AR068050A1 (es) Inhibidores de la polimerasa viral
AR050172A1 (es) Inhibidores de polimerasa viral
AR073659A1 (es) Compuetsos inhibidores de la hepatitis c
AR059292A1 (es) Inhibidores de la polimerasa viral
AR060949A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR047706A1 (es) Inhibidores de polimerasa viral
AR084588A1 (es) Compuesto heterociclico fusionado y su uso para el control de plagas
AR069596A1 (es) Regulador del crecimiento de plantas
AR054621A1 (es) 1-aril-4-ciclopropilpirazoles sustituidos
CO5631436A2 (es) Amidas y acidos derivados del bencimidazol para el tratamiento del dolor y la inflamacion
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
CO6180440A2 (es) Compuestos y composiciones como inhibidores de proteinquinasas
AR076252A1 (es) Inhibidores de la replicacion del vih
AR076775A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
BRPI0810929B8 (pt) uso de um composto de fórmula 1
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
AR061162A1 (es) Cetoenoles ciclicos sustituidos con alcoxialquilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure